NCT05484193

GnRH Agonist for Luteal Phase Support.

Comparison of Pregnancy Rates After Luteal Phase Support With GnRH Agonist Versus Progesterone - a Prospective Randomized Study

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 150 (actual)
• Sponsor: Shaare Zedek Medical Center · Academic / Other
• Sex: Female
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

Objective To assess the the efficacy of luteal support with GnRH agonist in patients undergoing IVF in antagonist-based hcg triggered cycles compared with standard luteal support with progesterone. Design prospective randomized controled study Subjects Patients who underwent antagonist-based cycles performed in the "Shaare Zedek Medical Center" IVF clinic between 2020 and 2022 Intervention Intranasal GnRH-agonist or vaginal Progesterone for luteal support. Main outcome measures Pregnancy and clinical pregnancy rates, ohss. The study cohort included 150 patients who underwent 164 cycles. A total of 127 cycles were included. Of them, 64 were treated with GnRH-a and 63 with progesterone. Hypothesis: This RCT suggests that GnRH-a for luteal phase support is associated with a higher positive β-hCG pregnancy rate and clinical pregnancy rate, compared with standard progesterone support in an antagonist-based protocol triggered with hCG, while maintaining a similar safety profile.

Conditions

• Use of GnRH Agonist Alone for Luteal Phase Support in Fresh IVF Cycles

Interventions

Type	Name	Description
DRUG	GnRH agonist	GnRH agonist alone for luteal phase support in fresh IVF embryo transfer cycles
DRUG	Progesterone	vaginal progesterone for luteal phase support

Timeline

• Start date: 2020-06-08
• Primary completion: 2022-04-15
• Completion: 2023-01-01
• First posted: 2022-08-02
• Last updated: 2022-08-02

Locations

1 site across 1 country: Israel